Development and Validation of a Prognostic Model for Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma Based on Preoperative Serum Prealbumin

References

• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol. 2023;11(2):480–489. doi:10.14218/JCTH.2022.00293
   PubMed Web of Science ®Google Scholar
• Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 2020;21(21):8165. doi:10.3390/ijms21218165
   PubMed Web of Science ®Google Scholar
• Pinero F, Dirchwolf M, Pessoa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020;9(6):1370. doi:10.3390/cells9061370
   PubMed Web of Science ®Google Scholar
• Loftus TJ, Brown MP, Slish JH, Rosenthal MD. Serum levels of prealbumin and albumin for preoperative risk stratification. Nutr Clin Pract. 2019;34(3):340–348. doi:10.1002/ncp.10271
   PubMed Web of Science ®Google Scholar
• Huo RR, Liu HT, Deng ZJ, et al. Dose-response between serum prealbumin and all-cause mortality after hepatectomy in patients with hepatocellular carcinoma. Front Oncol. 2020;10:596691. doi:10.3389/fonc.2020.596691
   PubMed Web of Science ®Google Scholar
• Ranasinghe RN, Biswas M, Vincent RP. Prealbumin: the clinical utility and analytical methodologies. Ann Clin Biochem. 2022;59(1):7–14. doi:10.1177/0004563220931885
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang H, Zhang L, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203–222. doi:10.1038/s41575-022-00704-9
   PubMed Web of Science ®Google Scholar
• Zhu GQ, Tang Z, Huang R, et al. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9(1):25. doi:10.1038/s41421-023-00529-z
   PubMed Web of Science ®Google Scholar
• Wang YY, Xiang BD, Ma L, et al. Development and validation of a nomogram to preoperatively estimate post-hepatectomy liver dysfunction risk and long-term survival in patients with hepatocellular carcinoma. Ann Surg. 2021;274(6):e1209–e1217. doi:10.1097/SLA.0000000000003803
   PubMed Web of Science ®Google Scholar
• Wang JC, Hou JY, Chen JC, et al. Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. Eur J Cancer. 2021;155:85–96. doi:10.1016/j.ejca.2021.07.009
   PubMed Web of Science ®Google Scholar
• Ruiz E, Pineau P, Flores C, et al. A preoperative nomogram for predicting long-term survival after resection of large hepatocellular carcinoma (>10 cm). HPB. 2022;24(2):192–201. doi:10.1016/j.hpb.2021.06.006
   PubMed Web of Science ®Google Scholar
• Kim JM, Kwon CHD, Joh JW, et al. Nomograms in hepatectomy patients with hepatitis B virus-related hepatocellular carcinoma. J Gastrointest Surg. 2019;23(8):1559–1567. doi:10.1007/s11605-018-04074-z
   PubMed Web of Science ®Google Scholar
• Smith SH. Using albumin and prealbumin to assess nutritional status. Nursing. 2017;47(4):65–66. doi:10.1097/01.NURSE.0000511805.83334.df
   PubMedGoogle Scholar
• Watanabe T, Shibata M, Nishiyama H, et al. Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer. Oncol Lett. 2014;7(2):373–377. doi:10.3892/ol.2013.1735
   PubMed Web of Science ®Google Scholar
• Arends J. Struggling with nutrition in patients with advanced cancer: nutrition and nourishment—focusing on metabolism and supportive care. Anna Oncol. 2018;29:ii27–ii34.
   Google Scholar
• Li J, Du M, Li H, et al. Low prealbumin levels were associated with increased frequency of hepatic encephalopathy in hepatitis B virus (HBV)-related decompensated cirrhosis. Med Sci Monit. 2023;29:e937772–937771. doi:10.12659/MSM.937772
   PubMed Web of Science ®Google Scholar
• Chen S, Shen B, Wu Y, et al. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy. Int Immunopharmacol. 2023;119:110228. doi:10.1016/j.intimp.2023.110228
   PubMed Web of Science ®Google Scholar
• Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(12):681–700. doi:10.1038/nrgastro.2015.173
   PubMed Web of Science ®Google Scholar
• Myron Johnson A, Merlini G, Sheldon J, Ichihara K. Scientific division committee on plasma proteins IFoCC, Laboratory M. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med. 2007;45(3):419–426. doi:10.1515/CCLM.2007.051
   PubMed Web of Science ®Google Scholar
• Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023;8(1):35. doi:10.1038/s41392-022-01304-4
   PubMed Web of Science ®Google Scholar
• Ferrero A, Vassallo D, Geuna M, et al. Immunonutrition in ovarian cancer: clinical and immunological impact? J Gynecol Oncol. 2022;33(6):e77. doi:10.3802/jgo.2022.33.e77
   PubMed Web of Science ®Google Scholar
• Luo Y, Xue Y, Mao L, et al. Prealbumin as a predictor of prognosis in patients with coronavirus disease 2019. Front Med Lausanne. 2020;7:374. doi:10.3389/fmed.2020.00374
   PubMed Web of Science ®Google Scholar
• Wang WK, Tu CY, Shao CX, et al. Impact of enhanced recovery after surgery on postoperative rehabilitation, inflammation, and immunity in gastric carcinoma patients: a randomized clinical trial. Braz J Med Biol Res. 2019;52(5):e8265. doi:10.1590/1414-431x20198265
   PubMed Web of Science ®Google Scholar
• Goyal P, Salem R, Mouli SK. Role of interventional oncology in hepatocellular carcinoma: future best practice beyond current guidelines. Br J Radiol. 2022;95(1138):20220379. doi:10.1259/bjr.20220379
   PubMed Web of Science ®Google Scholar
• Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21(36):10327–10335. doi:10.3748/wjg.v21.i36.10327
   PubMed Web of Science ®Google Scholar
• Sidali S, Trepo E, Sutter O, Nault JC. New concepts in the treatment of hepatocellular carcinoma. United European Gastroenterol J. 2022;10(7):765–774. doi:10.1002/ueg2.12286
   PubMed Web of Science ®Google Scholar
• Jihye C, Jinsil S. Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma. Liver Cancer. 2012;1(3–4):216–225. doi:10.1159/000343836
   PubMed Web of Science ®Google Scholar
• He Z, She X, Liu Z, et al. Advances in post-operative prognostic models for hepatocellular carcinoma. J Zhejiang Univ Sci B. 2023;24(3):191–206. doi:10.1631/jzus.B2200067
   PubMed Web of Science ®Google Scholar
• Yang JD, Kim WR, Park KW, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012;56(2):614–621. doi:10.1002/hep.25680
   PubMed Web of Science ®Google Scholar
• Rocha BMM, Dolan RD, Paiva CE, et al. Inflammation and performance status: the cornerstones of prognosis in advanced cancer. J Pain Symptom Manage. 2023;65(4):348–357. doi:10.1016/j.jpainsymman.2022.11.021
   PubMed Web of Science ®Google Scholar
• Dolan RD, Daly L, Sim WMJ, et al. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: implications for a clinically important framework in the assessment and treatment of advanced cancer. Clin Nutr. 2020;39(9):2889–2895. doi:10.1016/j.clnu.2019.12.024
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Tumen D, Heumann P, Gulow K, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines. 2022;10(12):3202. doi:10.3390/biomedicines10123202
   PubMed Web of Science ®Google Scholar
• de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374–403. doi:10.1016/j.ccell.2023.02.016
   PubMed Web of Science ®Google Scholar
• Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–855. doi:10.1136/gutjnl-2013-306627
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934
   PubMed Web of Science ®Google Scholar